We recently published a list of 10 Best Short-Term Stocks To Buy Right Now. In this article, we are going to take a look at where Cassava Sciences, Inc. (NASDAQ:SAVA) stands against other best short-term stocks with a buying opportunity for investors.
Thrilling highs, daunting lows, and the energized chase after the next big opportunity – this thoroughly defines the current stock market. In this roller coaster ride, momentum investing is an often-seen strategy piquing the investors’ interest, which involves capitalizing on continuing existing market trends. The approach holds onto the hope that high performers in the past will continue to perform better in the future as well. A curious subset within the strategy is the price momentum stocks, whose recent downturns are seen as an opportunity as they show potential for a swift rebound.
READ ALSO: 12 Best Multibagger Stocks to Buy in 2025
2025 has started with many changes, leading to complications in the U.S. stock market. The political changes, including the change in the U.S.’s stand in the Ukraine-Russia war, tariff changes leaning towards unfavorable imports, and the advent of artificial intelligence (AI) models from foreign countries, have brought down the stock value of many dominating leaders in the industry. For instance, CNBC reported a $750 billion drop in the tech industry’s Magnificent 7’s value as of March 10, 2025, owing to new tariffs. However, this decline has been attributed more to institutional selling than fundamental weaknesses. Discerning investors perceive it as a potential opportunity.
It is not just the tech giants feeling the heat. Price momentum stocks with negative one-year returns in the broader market continue to attract investors’ interest despite the fluctuations in the market. Despite the decline over the past year, these stocks have shown positive momentum in more recent periods, getting the attention of many analysts in the market. Such patterns are common in companies that underwent a restructuring, launched a promising product, or benefited from favorable market conditions. To identify these stocks, we must be willing to go deeper beyond the surface-level metrics, and hence, we present this article to you.
Before going into the article, however, investors are asked to approach the momentum investing strategy with caution. The strategy, particularly concerning stocks with recent negative returns, can be like walking a tightrope. We must consider the possibility of the factors that led to their decline, resurfacing in the future, or the short life of the recent positive momentum. Hence, in addition to the information we share in our article, thorough research alongside a well-defined exit strategy is highly recommended.
The pursuit of high returns can be tempting. Hence, investors are suggested to estimate the risk tolerance levels and long-term objectives and align them with their investment decisions. Even during tough times, the stock market presents investors with many opportunities. Discernment and prudence are required to make informed investment decisions that provide the best chance of generating an optimal return for your investment.
Our Methodology
We have used three key criteria to identify the 10 best short-term momentum stocks: a minimum decline of 30% over the past year, a minimum gain of 7.5% in the past month, and average daily trading volume of at least 100,000 shares. In addition, we have considered technical indicators focusing on stocks that recently crossed above their 20-day Simple Moving Average (SMA) and where the 20-day SMA exceeds the 200-day SMA, which signals a potential upward trend. To rank the list, we used the one-month returns. With it, we prioritized the most recent momentum performers. We have also considered the hedge fund interest from Insider Monkey’s Q4 2024 database for each stock on our list to project the level of market backing.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
A scientist in a lab coat working with a microscope in a research laboratory.
Cassava Sciences, Inc. (NASDAQ:SAVA)
Last 52 weeks return: -86.52%
Last 1 month’s return: 15.29%
No. of hedge fund portfolios: 10
Cassava Sciences, Inc. (NASDAQ:SAVA) is a Texas-based company engaged in clinical-stage biotechnology business and working on novel treatments for Alzheimer’s disease. Similarly, the company’s leading drug candidate is designed to restore protein function and reduce neuroinflammation. The company sets itself apart from its competitors by focusing on disease-modifying therapies rather than symptomatic relief. It has a global reach for its clinical trials and research.
Cassava Sciences, Inc. (NASDAQ:SAVA) has faced significant losses, plunging 86.52% over the past year, mainly reflecting challenges within the biotech sector. The company has been testing a new drug for the treatment of Alzheimer’s. The drug had passed the phase 1 trials and hence received huge expectations. However, during the latter part of 2024, the company’s Alzheimer’s treatment failed in Phase 3 testing, leading the stocks to plummet.
Despite the loss over the past year, recent trends show a 15.29% gain in the last month. The gain suggests some recovery potential, which was initiated by a license agreement concerning a new therapeutic application for Simufilam. Rick Barry, President and Chief Executive Officer at Cassava, has made the following statement in this regard.
“We are pleased to have entered a licensing agreement with Yale University, which allows us to build on the promising research of Angélique Bordey, PhD, Professor of Neurosurgery and Vice Chair of Research, Neurosurgery at Yale, to explore Simufilam’s potential as a treatment for TSC-related seizures”
While the 200-day SMA remains profoundly negative at -82.45%, the 20-day SMA has increased by 6.96%.
With 10 hedge fund portfolios from the Insider Monkey database still invested, some institutional confidence persists, making Cassava Sciences a risky yet high-rewarding stock for short-term traders.
Overall, SAVA ranks 8th on our list of 10 Best Short-Term Stocks To Buy Right Now. While we acknowledge the potential for SAVA as an investment, our conviction lies in the belief that some AI stocks hold more significant promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SAVA but that trades at less than 5 times its earnings check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires
